Revolution Medicines (RVMD) Research & Development (2019 - 2026)

Revolution Medicines' Research & Development history runs 8 years deep, the most recent figure standing at $344.0 million for Q1 2026.

• In Q1 2026, Research & Development rose 67.18% year-over-year to $344.0 million; the TTM figure through Mar 2026 stood at $1.1 billion (up 65.39% YoY), while the FY2025 annual figure was $987.3 million, up 66.72% from the prior year.
• Research & Development was $344.0 million for Q1 2026 at Revolution Medicines, up from $294.9 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $344.0 million in Q1 2026 to a low of $56.5 million in Q1 2022.
• Historically, Research & Development has averaged $153.0 million across 5 years, with a median of $134.9 million in 2024.
• Biggest YoY gain for Research & Development was 124.54% in 2023; the steepest drop was 22.05% in 2023.
• A 5-year view of Research & Development shows it stood at $66.1 million in 2022, then jumped by 124.54% to $148.5 million in 2023, then advanced by 26.68% to $188.1 million in 2024, then soared by 56.8% to $294.9 million in 2025, then grew by 16.62% to $344.0 million in 2026.
• The last three Research & Development figures came in at $344.0 million (Q1 2026), $294.9 million (Q4 2025), and $262.5 million (Q3 2025), per Business Quant data.